Your AI-Trained Oncology Knowledge Connection!

Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice : Episode 3

Video

February 20, 2023

Patients With Intermediate Stage HCC Suitable for TACE

Author(s):

Michael A. Morse, MD,Nicole Rich, MD

Experts review clinical studies evaluating TACE in patients with intermediate stage HCC.

EP: 1.Patients With Intermediate Stage HCC Unsuitable for TACE

EP: 2.Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

Now Viewing

EP: 3.Patients With Intermediate Stage HCC Suitable for TACE

EP: 4.HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

EP: 5.Selecting the Appropriate Frontline Treatment in Advanced HCC

EP: 6.Other Frontline Immunotherapy-based Combinations in Advanced HCC

EP: 7.Patient Profile 2: Advanced HCC Treated with Lenvatinib

EP: 8.Real-World Evidence for Lenvatinib in Advanced HCC

EP: 9.Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

EP: 10.Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

EP: 11.Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

EP: 12.Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

EP: 13.Treatment Considerations for Advanced HCC in Second Line and Beyond

EP: 14.Management of Child-Pugh B Patients with Advanced HCC

EP: 15.Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

May 14th 2025 - May 15th 2026

online-activity

Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

May 13th 2025 - Jun 18th 2025

online-activity

Video

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

May 9th 2025 - Jun 14th 2025

online-activity

Latest Conference Coverage

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Patients With Intermediate Stage HCC Suitable for TACE

EP: 1.Patients With Intermediate Stage HCC Unsuitable for TACE

EP: 2.Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab

EP: 3.Patients With Intermediate Stage HCC Suitable for TACE

EP: 4.HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC

EP: 5.Selecting the Appropriate Frontline Treatment in Advanced HCC

EP: 6.Other Frontline Immunotherapy-based Combinations in Advanced HCC

EP: 7.Patient Profile 2: Advanced HCC Treated with Lenvatinib

EP: 8.Real-World Evidence for Lenvatinib in Advanced HCC

EP: 9.Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab

EP: 10.Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond

EP: 11.Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

EP: 12.Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

EP: 13.Treatment Considerations for Advanced HCC in Second Line and Beyond

EP: 14.Management of Child-Pugh B Patients with Advanced HCC

EP: 15.Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

Newsletter

Latest CME

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Arizona

16th Annual International Symposium on Ovarian Cancer and Other Gynecological Malignancies™

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

Latest Conference Coverage